AB Science to host a live webcast on Tuesday, May 25, 2021

0


PRESS RELEASE

AB SCIENCE HOSTS LIVE WEBCAST ON TUESDAY MAY 25, 2021 ON MASITINIB RESULTS IN PROSTATE CANCER

Paris, May 21, 2021, 6 p.m. CET

AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on May 25, 2021 with key opinion leaders to discuss the recently reported results of the phase 2B / 3 trial of masitinib in prostate cancer.

The webcast call will take place on Tuesday, May 25, 2021 from 6:30 p.m. to 7:30 p.m. CET (12:30 p.m. to 1:30 p.m. ET).

The webcast will include presentations from three key opinion leaders:

  • Stéphane Oudard, MD, PhD, head of the clinical and translational research unit in oncology at the Georges Pompidou hospital in Paris, France
  • Theo M. de Reijke, MD, PhD, FEBU, Associate Professor at Amsterdam University Medical Centers, Amsterdam, The Netherlands
  • Olivier Hermine, MD, PhD, Head of Adult Hematology Staff at Necker Hospital in Paris, France, Chairman of the Scientific Committee of AB Science and Member of the French Committee Academy of Sciences

AB Science, along with these key opinion leaders, will provide:

  • An explanation of the rationale for positioning masitinib in the treatment of prostate cancer
  • Presentation of the results of the recently reported phase 2B / 3 clinical trial of masitinib in prostate cancer
  • A discussion of how masitinib is positioned in relation to current treatment options in prostate cancer

The presentation will be followed by a question-and-answer session with key opinion leaders and AB Science management.

Masitinib is a tyrosine kinase inhibitor designed to selectively target mast cells and macrophages, by inhibiting c-Kit, Lyn, Fyn and MCSFR-1 kinases, which are essential components of the tumor microenvironment, promoting angiogenesis. and tumor growth, and also contributing to tumorigenesis by suppressing the immune response.

April 29e, AB Science announced that its Phase 2B / 3 study of masitinib (AB12003) in chemotherapy-eligible metastatic castration-resistant prostate cancer (mCRPC) has met its predefined primary endpoint.

Login and webcast information

Webcast date: Tuesday, May 25, 2021. United States: 12:30 pm to 1:30 pm ET; Europe: 6.30pm-7.30pm CET
Number for the United States: +1 646 722 4916
Number for France: +33 1 70 71 01 59
International numbers (outside of the United States and France): Numbers for other countries are listed on the webcast page
Conference ID: 26441128 #

Webcast login page here

KOL biographies

The following key opinion leaders will participate in the webcast:

Stephane Oudard, MD, PhD

Stéphane Oudard is professor of oncology and head of the clinical and translational research unit in oncology at the Georges Pompidou hospital in Paris (2011), France. He is professor of oncology at René Descartes University, Paris, France.

Professor Oudard obtained his medical degree from the Hôtel-Dieu hospital, University of Paris, France (1993). At the end of his residency in medical oncology in Paris, Professor Oudard obtained his Master of Science at CHU Lariboisière-Saint Louis, Paris, France (1994) and his Doctorate at Institut Curie, Paris, France (1996). . He completed a 2 year cancer research fellowship at Georgetown University, Washington, DC, USA, before returning to Paris.

He is currently a member of the French Cancer Society, the European Society of Medical Oncology (ESMO, scientific committee) and the American Society of Clinical Oncology (ASCO). He joined the INSERM UMR-970 Paris Cardiovascular Research Center research unit (directed by Prof. Eric TARTOUR), a research team focused on immunomonitoring and immunotherapy of solid tumors. He is the deputy director of CARPEM, an integrated cancer research site. As a clinical researcher, Professor Oudard has been coordinator, researcher or co-investigator on several French, European and international phase I-III clinical trials. It has been widely implicated in the development of docetaxel, cabazitaxel, sorafenib, sunitinib, axitinib and everolimus in uro-oncologic tumors. He is a member of the French group GETUG.

His research interests include prostate and kidney cancers, translational research, angiogenesis, immunology, inhibition of glycolysis, and drug resistance. He is the principal investigator of the phase III trials of CABASTY in prostate cancer, of NEMIO in bladder cancer and co-leader of the BIONIKK trial on personalized medicine in the mRCC.

Professor Oudard is the author of 3 educational books, more than 348 scientific articles and 25 literature reviews published in various international journals.

Theo M. de Reijke, MD, PhD, FEBU

Dr Theo M. de Reijke is Associate Professor at the Medical Centers at the University of Amsterdam, Amsterdam, The Netherlands.

Theo M. de Reijke completed his medical training at the Free University of Amsterdam and worked from 1987 to 2018 as a urologist at UMC Amsterdam, site Academic Medical Center in Amsterdam. Since his retirement, he is still appointed to UMC Amsterdam for two days, supervising doctoral students and coordinating a bachelor’s program in oncology at the Faculty of Medicine of the University of Amsterdam. In 2004, he successfully defended his thesis on immunotherapy of bladder cancer.

Uro-oncology is his main area of ​​interest, in particular non-invasive muscle bladder cancer and upper tract tumors (new imaging modalities) and prostate cancer (focal therapy, new markers and imaging). ). He has been an active member of the European Organization for Research and Treatment of Cancer – Groupe Genito Urinary (EORTC-GU) for many years. After having been chairman of the subgroup on prostate cancer, he was elected secretary and then chairman of the EORTC-GU group until June 2009. In the Netherlands, he was chairman of the steering committee on cancer prostate cancer until 2019 and is a member of the bladder cancer guidelines committee.

He is a member of various international urological societies (eg NvU, EAU, AUA, Endourology Society), reviewer for several international journals and member of scientific boards for various journals. In 2011, he was voted critic of the month for European urology. He was chairman of the Dutch Resident Urology Training Program and chairman of the European Council of Urology Examination Board.

He represents the European Urological Association at EMA.

He was elected visiting professor at the Faculty of Medicine in Warsaw and he is an honorary member of the Polish and Romanian urological associations and was appointed honorary member of the Dutch Urological Association.

He is (co) author of over 250 peer-reviewed journal publications and has contributed to numerous book chapters. He has organized several national and international scientific meetings and is / has been coordinator of (inter) national trials in uro-oncology.

Olivier Hermine, MD, PhD
Olivier Hermine, MD, PhD is professor of hematology at Paris V-René Descartes University, head of the adult hematology staff at Necker hospital (Paris), member of the Académie des sciences and author of more than 700 international publications. Olivier Hermine is also co-founder of AB Science and responsible for its scientific committee.

About masitinib
Masitinib is a novel orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, cells important for immunity, by inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a variety of conditions in oncology, inflammatory diseases, and certain diseases of the central nervous system. In oncology, because of its immunotherapeutic effect, masitinib may have an effect on survival, alone or in combination with chemotherapy. By its activity on mast cells and microglia and therefore inhibiting the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKI), a class of targeted proteins whose action is essential in signaling pathways within cells. . Our programs only target diseases with high unmet medical needs, often fatal with short-term survival or rare or refractory to the previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the company’s principal compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine for oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and is listed on Euronext Paris (symbol: AB).

Further information is available on the AB Science website:
www.ab-science.com.

Forward-looking statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on plans, objectives, intentions and expectations regarding financial results, events, operations, future services, development. of products and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” and other similar terms. Although AB Science believes that these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties which are difficult to predict and generally beyond the control of AB Science and which may involve the actual results and events differ materially from those expressed, implied or anticipated in the forward-looking information and statements. These risks and uncertainties include uncertainties related to the development of the Company’s products that could fail or to the marketing authorizations granted by the competent authorities or, more generally, any factor that could affect the marketing capacity of the products developed by AB Science. , as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in chapter 4 “Risk factors” of the AB Science reference document filed with the ‘AMF on November 22, 2016, under number R. 16-078. AB Science disclaims any obligation or commitment to update forward-looking information and statements, subject to applicable regulations, in particular Articles 223-1 and following. of the AMF general regulations.

For more information, please contact:

AB Science
Financial communication and media relations
[email protected]

Media Relations – United States

RooneyPartners
Kate barrette
[email protected]

+1 646 432 0191

Media relations – France

NewCap
Arthur Rusty
[email protected]

+33 (0) 1 44 71 00 15

  • Webcast Masitinib Prostate cancer vEng VF



Source link

Leave A Reply

Your email address will not be published.